THE FIFTH INTERNATIONAL CONFERENCE ON:

MALARIA VACCINES FOR THE WORLD
8-10 May 2019, University of Oxford, Oxford, UK

FINAL ORAL & POSTER PROGRAMME

MVW 2019

SCIENTIFIC ADVISORY PANEL

Local Organiser: Simon Draper (University of Oxford, UK)
Jane Achan (LSHTM/MRC, The Gambia)
Evelina Angov (Walter Reed Army Institute of Research, USA)
Sumi Biswas (University of Oxford, UK)
Chetan Chitnis (Institut Pasteur, France and ICGEB, India)
Alassane Dicko (University of Bamako, Mali)
Carlota Dobaño (Barcelona Institute for Global Health, Spain)
Denise Doolan (James Cook University, Australia)
Sócrates Herrera (Malaria Vaccine and Drug Development Center, Colombia)
Stephen L. Hoffman (Sanaria, USA)
Adrian Hill (University of Oxford, UK)
Melissa Kapulu (KEMRI-Wellcome Trust, Kenya)
Shahid Khan (Leiden University Medical Centre, Netherlands)
Rick King (PATH’s Malaria Vaccine Initiative, USA)
Francine Ntoumi (Fondation Congolaise pour la Recherche Médicale, Republic of the Congo)
Ally Olotu (Ifakara Health Institute, Tanzania)
Melissa Penny (Swiss Tropical and Public Health Institute, Switzerland)
Robert Seder (National Institutes of Health, USA)
Sodiumon Sirima (Groupe de Recherche Action en Santé (GRAS), Burkina Faso)
Takafumi Tsuboi (Ehime University, Japan)
Johan Vekemans (World Health Organisation, Switzerland)
Nicola Viebig (European Vaccine Initiative, Germany)
Eileen Villasante (Naval Medical Research Center, USA)
Hedda Wardemann (German Cancer Research Centre, Germany)
Rana Chattopadhyay (CBER/FDA, Silver Spring, Maryland, USA)
SESSION 1: OPENING PLENARY SESSION

Moderator: Simon Draper
(University of Oxford, Oxford, UK)
09.30-10.00
‘Subunit vaccines for malaria – getting there!’
Adrian V.S. Hill
(University of Oxford, Oxford, UK)
10.00-10.30
‘Developing vaccines to battle the complex parasites that cause malaria in heterogeneous populations is not for the faint of heart: The PfSPZ experience’
Stephen Hoffmann
(Sanaria Inc., Maryland, USA)
10.30-11.00
Coffee Break & Posters Set-Up

SESSION 2: PFSPZ-BASED VACCINES: PHASE 3 TO LICENSURE TO DEPLOYMENT TO USE IN ELIMINATION CAMPAIGNS TO NEXT GENERATIONS

Moderators: Said Jongo (Ifakara Health Institute, Ifakara, Tanzania) and Marcel Tanner (Swiss TPH, Switzerland)
11.00-11.15
‘Finalizing an immunization regimen for PfSPZ Vaccine for Phase 3 clinical trials in non-immunes’
Stephen L. Hoffman
(Sanaria Inc., Maryland, USA)
11.15-11.30
‘Finalizing an immunization regimen for PfSPZ Vaccine for Phase 3 clinical trials in semi-immune adults in Africa’
Said Jongo
(Ifakara Health Institute and Bioko Island Malaria Elimination Program)
11.30-11.45
‘Current status of and medium-term plans for PfSPZ Vaccine’
Thomas L. Richie
(Sanaria Inc., Maryland, USA)
11.45-12.00
‘Plans for use of PfSPZ Vaccine for Geographically Focused Elimination Campaigns’
Salim Abdulla
(Ifakara Health Institute and Bioko Island Malaria Elimination Program)
12.00-12.15
‘Developing a PfSPZ-CVac regimen that provides high level protection against heterologous CHMI’
Agnes Mwakingwe
(Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH, Bethesda, Maryland, USA)
12.15-12.30
‘Current status of early arresting genetically altered PfSPZ vaccines, PfSPZ-GAP3KO’
Ashley Vaughan
(Seattle Children’s Hospital Research Foundation, Seattle, Washington, USA)
12.30-12.45
‘Current status of early arresting genetically altered PfSPZ vaccines, PfSPZ-GAP3KO’

SESSION 3: PFSPZ-BASED VACCINES: INNOVATIONS AND IMMUNOLOGY TO IMPROVE EFFICACY AND REDUCE COST OF GOODS

Moderators: Patrick Duffy (LMIV, NIAID, NIH) and Peter F. Billingsley (Sanaria Inc., Maryland, USA)
13.45-14.00
‘Production of fully infectious, immunogenic PfSPZ in vitro’
Abraham Eappen
(Sanaria Inc., Maryland, USA)
14.00-14.15
‘Hybrid strains and mixed strains of PfSPZ for increasing genetic diversity’
B. Kim Lee Sim
(Sanaria Inc., Maryland, USA)
14.15-14.30
‘Development of late liver stage arresting genetically attenuated PfSPZ and parasites expressing heterologous antigens’
Shahid Khan and Chris Janse
(Leiden University Medical Center, Leiden, The Netherlands)
14.30-14.45
‘Development of late liver stage arresting genetically attenuated PfSPZ and parasites expressing heterologous antigens’
Stefan Kappe
(Seattle Children's Hospital Research Foundation, Seattle, Washington, USA)
14.45-15.00
‘Improving immunogenicity with adjuvants’
Sumana Chakravarty
(Sanaria Inc., Maryland, USA)
15.00-15.15
‘What have we learned and not learned from immunological studies during vaccine efficacy studies?’
Claudia Daubenberger
(Swiss TPH, Switzerland)
15.15-15.30
‘Complementing protection with human monoclonal antibodies’
Stephen L. Hoffman
(Sanaria Inc., Maryland, USA)
15.30-16.00
Tea Break & Posters

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.
SESSION 4: RECENT ADVANCES – BLOOD-STAGE VACCINES

Moderators: Evelina Angov (Walter Reed Army Institute of Research, USA) and Chetan Chitnis (Institut Pasteur, France & ICGEB, India)

16.00-16.15
‘Safety, immunogenicity and efficacy of the Plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a Phase I/IIa clinical trial’
Angela M. Minassian1, Sarah E. Silk1, Jordan R. Barrett1, Ian D. Poulton1, Celia H. Mitton1, Ruth O. Payne1, Thomas A. Rawlinson1, Megan Baker1, Raquel Lopez Ramon1, Fernando Ramos Lopez1, Nick J. Edwards1, Katherine J. Ellis1, Carolyn M. Nielsen1, Doris Quinkert1, Lea Barfod1, Kazutoyo Miura2, Ababacar Diouf2, Yrene Themistocleous1, Pedro Folegatti1, Daniel Silman1, Mehreen Datoo1, Willem A. de Jongh3, Robert Smith1, Eleanor Berrie1, Danielle Morelle4, Marc Lievens5, Amy R. Noe5, Carter L. Diggs6, Lorraine A. Soisson6, Rebecca Ashfield1, Carole A. Long1, Fay L. Nugent1, Alison M. Lawrie1 and Simon J. Draper1
(1 The Jenner Institute, University of Oxford, United Kingdom; 2 Laboratory of Malaria and Vector Research, NIAID/NIH, USA; 3 ExpreS2ion Biotechnologies, Denmark; 4 GSK, Wavre, Belgium; 5 Leidos Life Sciences, USA; 6 Malaria Vaccine Development Program, USAID, USA)

16.15-16.30
‘Superior antigen-specific T follicular helper (Tfh) cell responses to blood-stage malaria antigen RH5 are induced with a protein/AS01 vaccine platform as compared to heterologous viral vectors’
Carolyn M. Nielsen, Ane Ogbe, Isabela Pedroza-Pacheco, Susanne Doeleman, Sarah E. Silk, Jordan R. Barrett, Sean C. Elias, Ruth O. Payne, Angela M. Minassian, Simon J. Draper and Persephone Borrow
(University of Oxford, Oxford, UK)

16.30-16.45
‘Status of PfEMP1 vaccine development’
Louise Turner, Morten Nielsen, Ali Salanti, Thor G. Theande and Thomas Lavstsen
(University of Copenhagen, Copenhagen, Denmark)
SESSION 5: RECENT ADVANCES – SPOROZOITE AND LIVER-STAGE VACCINES

Moderators: Johan Vekemans (WHO, Geneva, Switzerland) and Eileen Villasante (Naval Medical Research Center, USA)

08.30-08.45
‘Qualitative aspects of antibody responses to malaria vaccines after primary and booster vaccination’
Carolina Dobaño
(IGlobal Barcelona Institute for Global Health Hospital Clinic – Universitat de Barcelona, Barcelona, Catalonia, Spain)

08.45-09.00
‘In vitro and in vivo correlates for down-selection of CSP based immunotherapeutics against malaria’
Sheetij Dutta, Alexis Bilzer, Merricka Livingstone, Mark Langowski, Farhat Khan, Kim Soto, Cathy Zou, Rajeshwer S. Sankhala, Viseth Ngauy, M. Gordon Joyce and Adrian Batchelor
(1 Structural Vaccinology Laboratory, Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 2 Liver Stage Laboratory, Malaria Department, Naval Medical Research Center, Silver Spring, Maryland, USA; 3 Structural Biology, U.S. Military HIV Research Program, Walter Reed Army Institute, Silver Spring Maryland USA; 4 Henry M. Jackson Foundation for the Advancement of Medicine, Bethesda, Maryland, USA)

09.00-09.15
‘N-terminal region of Plasmodium falciparum circumsporozoite protein mediates immune evasion by hijacking a complement inhibitor’
Ayman Khatib, Rauna Riva, Mikko Kyrlund, Ossi Turunen, Adrian J.F. Luty, Robert Sauerwein and Seppo Meri
(1 Translational Immunology Research Program, University of Helsinki, Finland; 2 School of Forest Sciences University of Eastern Finland, Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA; 2 EpiVax, Inc., Providence, Rhode Island, USA)

09.15-09.30
‘Intravenous administration of viral vectors for potent induction of liver resident T cells’
Alexandra J. Spencer, Andrés Noé, Marta Ulaszewska, Mehreen Datoo, Daniel Jenkin, Duncan Bellamy, Amy Flaxman, Ali Husainy, Katie J. Ewer and Adrian V.S. Hill
(The Jenner Institute, University of Oxford, Oxford, UK)

09.30-09.45
‘Prime-target immunisation with liver-stage malaria vaccines: A first-in-human challenge trial’
(The Jenner Institute, University of Oxford, Roosevelt Drive, Oxford, UK)

09.45-10.00
‘Clinical safety and protective efficacy after immunization with genetically modified Plasmodium berghei sporozoites expressing P. falciparum circumsporozoite protein in a first-in-human Phase1/2a trial’
António M. Mendes
(on behalf of the PbVac consortium)

10.00-10.15
‘Systems-based approaches to defining effective targets for intervention against malaria’
(1 Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia; 2 QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia)

10.15-10.45
Coffee Break & Posters

SESSION 6: SPECIAL PATH/WHO SESSION

‘The Phased Introduction and Evaluation of the RTS,S/AS01 Malaria Vaccine in Children in Ghana, Kenya, and Malawi’
Organizers: World Health Organization, Geneva, Switzerland

10.45-11.00
‘The need for New Tools to Fight Malaria’
Mary Hamel
(WHO, Geneva, Switzerland)

11.00-11.15
‘Vaccine Introduction of the RTS,S/AS01 Malaria Vaccine: Implementation Progress and the Response of Communities’
Teriwa Mzengeza
(Manager of the Expanded Programme on Immunization, Ghana Health Service)

11.15-11.30
‘Evaluation of RTS,S/AS01 in the Context of Routine Use: Measuring Feasibility, Safety, and Impact’
Patricia Njogu
(Medical Officer, World Health Organization)

11.30-12.00
‘Obstacles to and Opportunities for Reaching High Vaccine Uptake’
Margaret Gyapong
(Centre for Health Policy and Implementation Research, University of Health and Allied Science, Ghana)

12.00-12.15
‘Post-authorization Evaluation: Concurrent Phase IV Studies’
Nekoya Otsyula
(GSK Vaccines, Kenya & East Africa)

12.15-12.30
Closing Remarks:
‘The Path Forward’
Mary Hamel
(WHO, Geneva, Switzerland)

12.30-13.15
Lunch Break & Posters

SESSION 7: CELLULAR AND ANTIBODY VACCINE IMMUNOLOGY

Moderators: Carla Dobaño (SGlobal Barcelona Institute for Global Health Hospital Clinic – Universitad de Barcelona, Barcelona, Catalonia, Spain) and Ally Olotu (Ifakara Health Institute, Tanzania)

13.15-13.30
‘Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi’
Sundos Khan, Matthew Parrillo, Andres H. Gutierrez, Frances Terry, Leonard Moise, William D. Martin and Anne S. De Groot
(1 Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA; 2 EpiVax, Inc., Providence, Rhode Island, USA)

13.30-13.45
‘Prime-target immunisation with liver-stage malaria vaccines enhances T cell immunogenicity’
Amy Flaxman, Duncan Bellamy, Rebecca Makinson, Jonathan Sheridan, Kate Harrison, Richard Morter, Mehreen Datoo, Daniel Jenkin, Fernando Ramos-Lopez, Ian Poulton, Rachel Roberts, Alison M. Lawrie, Alexandra J. Spencer, Katie J. Ewer and Adrian V.S. Hill
(The Jenner Institute, University of Oxford, Oxford, UK)

13.45-14.00
‘The adjuvant GLA-SE promotes strong circulating Tfh cell expansion and emergence of public TCR clonotypes in malaria pre-exposed volunteers vaccinated with PZTA’

#MVW2019
VIEW FUTURE EVENTS AT WWW.MEETINGSMANAGEMENT.COM
SESSION 8: STRUCTURE-GUIDED VACCINE DESIGN AND RECENT ADVANCES IN TRANSMISSION-BLOCKING VACCINES

Moderators: Takafumi Tsuboi (Ehime University, Japan) and Denise Doolan (James Cook University, Australia)

14.45-15.00
‘Structural basis for development of a Plasmodium falciparum transmission blocking vaccine targeting the 6-cysteine rich Pfs230 or the Pfs230-Pfs48/45 protein complex’
Kavita Singh1, Martin Burkhart2, Raul Herrera2, Apostolis Gittis1, Sofia Nakuchima2, Olga Muratova3, Emily Kelhoefer4, Karine Reiter2, Margery Smelkinson3, Bruce J. Swihart5, Baoshan Zhang1, Nicholas J. Macdonald1, Patrick E. Duffy6, David Garboczi1 and David L. Narum2

1 (Structural Biology Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA; 2 Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA; 3 Biological Imaging Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA; 4 Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA; 5 Program in Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA)

15.00-15.15
‘Improving the potency and therefore durability of transmission-blocking vaccines through structure-based vaccine design’
C. Richter King1, Randall MacGill2, Kazutoyo Miura3, Robert W. Sauerwein4, William R. Schieff5 and Jean-Philippe Julien6

1 (PATH’s Malaria Vaccine Initiative, Washington DC, USA; 2 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA; 3 Fdboud University Medical Center, Nijmegen, Netherlands; 4 The Scripps Research Institute, La Jolla, California, USA; 5 Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada and Departments of Biochemistry and Immunology, University of Toronto, Toronto, Ontario, Canada)

15.15-15.30
‘Maturation of potent cross reactive antibodies to Plasmodium falciparum circumsporozoite protein in humans’
Rajagopal Murugan

(1 German Cancer Research Centre, DKFZ, Heidelberg, Germany)

15.30-15.45
‘Characterization of antimalarial monoclonal antibodies reveals synergistic epitopes in the Plasmodium falciparum R5-CyRPA-Ripr invasion complex’

(1 University of Oxford, Oxford, UK)

15.45-16.00
‘From structure to malaria vaccine immunogen’
Matthew Higgins

(University of Oxford, Oxford, UK)

16.00-16.15
‘Pfs48/45 as a malaria transmission-blocking vaccine’
David Mekhaiel1, Arianna Marin1, Florian Brod1, Rebecca Dabbs1, Katherine Ellis1, Yuanjuan Li2, Marija Zaric1, Gaurav Gupta1, Kazutoyo Miura2, Carole A. Long3 and Sumi Biswas1

1 (The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK; 2 Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland, USA; 3 Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Cambridge, UK; 4 ExpresION Biotechnologies, Denmark)

14.30-15.00
Tea Break & Posters
SESSION 9: LATEST ADVANCES IN VACCINES AND CHMI FOR P. VIVAX

Moderator: Shahid Khan
(Leiden University Medical Centre, Netherlands)

09.00-09.15

‘Reticulocyte-derived exosomes: A new antigen discovery and vaccine delivery platform against Plasmodium vivax malaria’
Miriam Díaz-Varela1, Melissa Gualdrón-López2,3, Joan Segui-Barber3, Ricardo Lazaurica-Valdemoros3, Nuria Izquierdo-Useros4, Javier Martínez-Picado5,6, Carmen Fernández-Becerra7,8 and Hernando A. del Portillo2,9,10
(1) ISGlobal, Hospital Clinic – Universitat de Barcelona, Barcelona, Spain; 2 IGTI Institut d’Investigació Germans Trias i Pujol, Badalona, Spain; 3 Nephrology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 4 IrisCaixa AIDS Research Institute, Badalona, Spain; 5 Institute Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

09.15-09.30

‘Assessment of P. vivax sporozoite and blood-stage CHMI in healthy UK adults’
Angela M. Minassian1, Yrene Themistocleous2, Sarah E. Silk3, Jordan R. Barrett4, Carolyn M. Nielsen5, Doris Quinkert1, Ian D. Poulton1, Fernando Ramos Lopez6, Celia H. Mitton1, Thomas A. Rawlinson7, Nick J. Edwards1, Katherine J. Ellis1, Megan Baker1, Raquel Lopez Ramon1, Jee-Sun Choi1, Florian Bach8, Wiebke Nahrendorff9, Alison C. Kemp1, Philip Spence2, Andrew M. Blagborough1, Iona J. Taylor1, Fay L. Nugent1, Kimberly J. Johnson1, Alison M. Lawrie1, Wiebke Nahrendorff1, Julian C. Rayner1, Wanlapa Roobsoong1, Ketsumo Satafakong1, Sumi Biswas4 and Simon J. Draper1
(1) The Jenner Institute, University of Oxford, Oxford, UK; 2 School of Biological Sciences, University of Edinburgh, Edinburgh, UK; 3 Welcome Sanger Institute, Wellcome Genome Campus, University of Cambridge, Cambridge, UK; 4 Infection & Immunity Section, Sir Alexander Fleming Building, Imperial College of Science, Technology and Medicine, London, UK; 5 Mahidol Vivax Research Unit (MVRU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

09.30-09.45

‘Malaria vaccine candidate based on Duffy binding protein elicits strain 09.30-09.45

Moderator: Paula Bettencourt
(1) Multi-Vaccines Development Program, New Delhi, India; 2 International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India; 3 USBT, Guru Gobind Singh Indraprastha University, New Delhi; 4 Syngene International Ltd., Bangalore, India; 5 Gennova Biopharmaceuticals Pvt. Ltd., Pune, India; 6 Infectious Disease Research Institute (IDRI), Seattle, USA; 7 PATH Malaria Vaccine Initiative, Seattle, USA; 8 Institut Pasteur, Paris, France

09.45-10.00

‘Molecular basis for inhibition of Plasmodium vivax reticulocyte invasion by a vaccine-induced broadly neutralising human monoclonal antibody’
(1) The Jenner Institute, University of Oxford, Oxford, UK; 2 Department of Biochemistry, University of Oxford, Oxford, UK; 3 Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK; 4 Faculty of Public Health, Mahidol University, Bangkok, Thailand; 5 Shoklo Malaria Research Unit, Mae Sot, Thailand; 6 Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK; 7 Singapore Immunology Network, Singapore, Singapore; 8 Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

10.00-10.30

Coffee Break & Posters

SESSION 10: NOVEL APPROACHES TO ANTIGEN DISCOVERY, VACCINE DELIVERY AND ADJUVANTS

Moderator: Sumi Biswas
(University of Oxford, Oxford, UK) and Rick King (PATH’s Malaria Vaccine Initiative, USA)

10.30-10.45

‘Bacterial superglues to accelerate malaria vaccine generation’
Mark Howarth (University of Oxford, Oxford, UK)

10.45-11.00

‘Strategic Overview: WRAIR’s Next Generation Adjuvanted P. falciparum CSP Vaccine Candidates in Clinical Development, PICSP-SAPN and full length, soluble PICSP’
Evelina Angov1, Sheetij Dutta1, Zoltan Beck2, Gary Matyas2 and Viseth Ngyu3
(1) Walter Reed Army Institute of Research, Malaria Vaccine Branch, Silver Spring, Maryland, USA; 2 Walter Reed Army Institute of Research, Military HIV Research Program, Silver Spring, Maryland, United States

11.00-11.15

‘APC-targeted DNA vaccination against RHs induces Plasmodium falciparum-specific neutralizing antibodies and T cell responses’
Louise Björkman1, Åmar Gundjesson1, Ganesh Ram Visweswaran1, Geneviève M. Labbé2, Doris Quinkert1, Simon J. Draper1, Bjarte Bogen1 and Ranveig Braathen1
(1) Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 2 Jenner Institute, University of Oxford, Oxford, UK

11.15-11.30

‘Safety, tolerability and immunogenicity of ChAd63 and MVA expressing P. falciparum RH5 in African adults, young children and infants’
Ally Oluto1,2,3, Saumu Ahmed1,4, Maximilian Mpina1, Willmina Kalinga1, Florence Milano1, Mohamed Rashidi1, Said Jongo1, Yrene Themistocleous2,3, Jordan R. Barrett4, Alison M. Lawrie1, Fay L. Nugent1, Sarah E. Silk5, Angela M. Minassian6 and Simon J. Draper1
(1) Health Institute; 2 KEMRI-Wellcome Trust Research Programme; 3 The Jenner Institute, University of Oxford, Oxford, UK

11.30-11.45

‘Post-genome unbiased strategies for discovery of malaria vaccine candidates by innovative wheat germ cell-free technology’
Takafumi Tsuibo
(Division of Malaria Research, Proto-Science Center, Ehime University, Japan)

11.45-12.00

‘Identification of novel antigens presented by MHC class I using immunopeptidomics for vaccines against malaria’
Paul Bettencourt1, Camila R.R. Barbosa2, Valerie Soulard1, Julius Müller1, Ahmed Saliman4, Katie Plummer1, Maullary Bordessoulles1, Annalisa Nicasrti1, Shahid M. Khan1, Chris J. Janse1, Hiroshi Suemizu2, Alex J. Spencer1, Nicola Ternette1, Robert Sauerwein3, Dominique Mazier4, Caroline Junqueira2,3 and Adrian Y.S. Hill1
(1) The Jenner Institute, University of Oxford, Oxford, UK; 2 Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil; 3 Sorbonne Universités, UPMC, CR7, INSERM, U1135, CNRS, ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; 4 Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands; 5 Central Institute for Experimental Animal, Kawasaki, Kanagawa, Japan; 6 Parasitology, Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands; 7 Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA; 8 Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA

12.00-12.15

‘Overview of Malaria Vaccines Regulation by FDA’
Rana Chattopadhay and R. Douglas Pratt
(Division of Vaccines and Related Product Applications (DVRPA), Office of Vaccines Review and Research (OVRR), Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA)

12.15-12.30

Closing Remarks
12.30
Lunch Break & Posters Breakdown & Departure
\textbf{Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX-313 in a Phase I First-in-Human Trial}


(1) NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust and Faculty of Medicine, University of Southampton, Southampton, UK; 2 The Jenner Institute, University of Oxford, Oxford, UK; 3 Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA; 4 GSK Vaccines, Ware, Belgium; 5 Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland; 6 Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK; 7 OSIVAX, Lyon, France

\textbf{Targeting PRfH3 to APCs via MHC class II potentiates viral vector immunization against malaria}

Arnar Gudjonsson, Louise Bjerkman, Geneviève M. Labbé, Simon J. Draper, Ranveig Braathen and Bjarme Bogen

(1) Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 2 Jenner Institute, University of Oxford, Oxford, UK

\textbf{Synergistic antigen discovery for a blood-stage malaria vaccine}

Jee-Sun Cho, Joseph J. Ringworth, Doris Quirkert, Amelia M. Lias, Sarah E. Silk, Jordan R. Barrett, David Poulido and Simon J. Draper

(University of Oxford, Oxford, UK)

\textbf{Memory B responses and functional antibodies induced by a vaccine candidate against malaria in pregnancy using in vitro assays}

T. Houtshoetbeke, D. Berry, K. Gbedeandie, H. Hasang, S. Rogerson and A. Luby

(1) University of Melbourne, Department of Medicine, Australia; 2 Peter Doherty Institute, Laboratory of Malaria, Department of Immunology and Microbiology, University of Melbourne, Australia; 3 Université Paris DESCARDES, UMR216-MERIT, Department of Immunology, Paris, France; 4 Institut de Recherche Clinique du Bénin, Cotonou, Benin; 5 Centre d’Étude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Faculté des Sciences de la Santé de Cotonou, Benin; 6 Institut de Recherche pour le Développement, Laboratory of Parasitology, Cotonou, Benin

\textbf{The Toll-Like Receptor 2 agonist PEG-Pam,Cys as an immunochemo prophylactic and immunochemo therapeutic against the liver and transmission stages of malaria parasites}

Mietar Ernest, Carol Hunjia, Yuka Arakura, Yohei Haraga, Hussien M. Abkallo, WeiXiang Zeng, David C. Jackson, Brendon Chua and Richard Culleton

(1) Malaria Unit, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan; 2 Department of Immunology and Microbiology, The Pohjola Institute for Infection and Immunology, The University of Melbourne, Parkville, Victoria, Australia; 3 Research Center for Vector Control, Hokkaido University, Sapporo, Japan; 4 Global Institute for Collaborative Research and Education, Hokkaido University, Sapporo, Japan

\textbf{Reference reagents to support Plasmodium falciparum and Plasmodium vivax vaccine development and diagnostics}

Lynne M. Harris, Eleanor Akinson, Peter Rigsby and Paul W. Bowyer

(National Institute for Biological Standards and Control (NIBSC), South Mimms, UK)

\textbf{Can the RTS,S/AS01 vaccine be used to accelerate P. falciparum elimination?}

Cynthia K. Lee

(PATH’s malaria Vaccine Initiative, Washington DC, USA)

\textbf{Preclinical generation and evaluation of an RH5.2-VP vaccine for blood-stage malaria}

Lloyd D.W. King, David Poulido, Quirkert, Amelia M. Lias, David J. Pattinson, Yu Zhou, Jing Jin, Matthew K. Higgins, Mark Howarth, Sumi Biswas, Jenny M. Reimer, Karin Lövgren Bengtsson and Simon J. Draper

(University of Oxford, Oxford, UK)

\textbf{Immune protection in a relapsing P. cymolugi rhesus model induced by a chemophylaxis with sporozoite (CPS) immunization under atovaquone-proguanil followed by primaquine}

S. Pichyangkul, M.D. Spring, K. Yongvanitchit, U. Kum-Art, A. Limsalaksode, R. Im-Erbsin, R. Ubalee, P.L. Smith, B.A. Vesely and N.C. Waters

(1) Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand; 2 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., USA

\textbf{Characterisation of monoclonal antibodies to Plasmodium falciparum CryPRA reveals multiple synergistic epitopes}

Anne S. Knudsen, Maria Basili, Melanie R. Walker, Simon J. Draper and Lea K. Barford

(1) University of Copenhagen, Department of Immunology & Microbiology, Centre for Medical Parasitology, Copenhagen, Denmark; 2 University of Oxford, Jenner Institute, Oxford, UK

\textbf{Reduced immunogenicity of an experimental vaccine against malaria is associated with prior exposure to infection: A role for Regulatory T cells?}

Richard Morter, Oliver Hague, Amy Flaxman, Lisa Nebie, Alfred Tiong, Sodionmon B. Sirima, Adrian V.S. Hill and Katie J. Ewer

(1) Jenner Institute, Nuffield Dept of Medicine, University of Oxford, UK; 2 Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; 3 Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso

\textbf{Investigation of two vaccine-delivery platforms to enhance immunogenicity and transmission-blocking activity of malaria vaccine candidate Prs25}


(1) Jenner Institute, University of Oxford, Oxford, UK; 2 Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

\textbf{Validation of a Plasmodium falciparum qPCR assay, suitable for real time follow up and use as the primary diagnosis tool in Phase IIa CHMI clinical trials}

Nick J. Edwards, Katherine J. Ellis, Caitlin Blundell, Susann Blundell, Ming Chang, Sean Murphy, Meheren Dato, Daniel Jenkin and Katie Ewer

(1) The Jenner Institute, University of Oxford, Oxford, UK; 2 Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford, UK; 3 Malaria Human Challenge Center, Center for Infectious Disease Research, Seattle, Washington, USA

\textbf{Characterisation of the humoral responses induced by the Plasmodium falciparum Blood-Stage Vaccine RHF1.1ASOB1}


(1) The Jenner Institute, University of Oxford, Oxford, UK; 2 Centre for Infectious Diseases, Parasitology, National Institute for Biological Standards and Control, MHRA, Blanche Lane, Potters Bar, UK; 3 Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany; 4 Kenya Medical Research Institute - Wellcome Trust Research Program, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya

\textbf{Synergistic antigen discovery for a blood-stage malaria vaccine}

Jee-Sun Cho, Joseph J. Ringworth, Doris Quirkert, Amelia M. Lias, Sarah E. Silk, Jordan R. Barrett, David Poulido and Simon J. Draper

(University of Oxford, Oxford, UK)

\textbf{Evaluation of humanised mice for blood-stage malaria vaccines}


(1) The Jenner Institute, University of Oxford, Oxford, UK; 2 Centre for Infectious Diseases, Parasitology, National Institute for Biological Standards and Control, MHRA, Blanche Lane, Potters Bar, UK; 3 Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany; 4 Kenya Medical Research Institute - Wellcome Trust Research Program, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya

\textbf{Prime-Target Immunisations: Comparing Cellular and Humoral Immune Responses after administration of intramuscular and intravenous vaccinations against ME-TRAP}


(University of Oxford, Oxford, UK)
The MVW 2019 Scientific Advisory Panel and the organizers would like to acknowledge the support of the following sponsors:

- DNAvaccine.com
- mvi PATH
- Malaria World
- MW Journal
- Sanaria
- EVI
- Malaria NO MORE
- Aldevron
- Nature Gene Therapy
- Inovio Pharmaceuticals
- Vismедерi
- Mymetics